Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial
Author(s) -
Jawad H. Butt,
Pardeep S. Jhund,
Jan Bělohlávek,
Rudolf A. de Boer,
ChernEn Chiang,
Akshay S. Desai,
Jarosław Dróżdż,
Adrian F. Hernandez,
Silvio E. Inzucchi,
Tzvetana Katova,
Masafumi Kitakaze,
Mikhail Kosiborod,
Carolyn S.P. Lam,
Anna Maria Langkilde,
Daniel Lindholm,
Erasmus Bachus,
Felipe A. Martínez,
Béla Merkely,
Magnus Petersson,
Jose F. Kerr Saraiva,
Sanjiv J. Shah,
Muthiah Vaduganathan,
Orly Vardeny,
Ulrica Wilderäng,
Brian Claggett,
Scott D. Solomon,
John J.V. McMurray
Publication year - 2022
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.122.061754
Subject(s) - medicine , dapagliflozin , heart failure , ejection fraction , hazard ratio , clinical endpoint , tolerability , randomized controlled trial , canadian cardiovascular society , cardiology , confidence interval , adverse effect , myocardial infarction , diabetes mellitus , angina , type 2 diabetes , endocrinology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom